Program Type: CTAF

Alzheimer’s Disease

Jul 2021 | Assessment

Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, ICER’s revised Evidence Report finds the price range needed to reach standard cost-effectiveness thresholds for Aduhelm is $3,000-$8,400, representing an 85%-95% discount from the announced list price. At our July 15 public meeting, a roundtable of key stakeholders — […]